Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Jul 23, 2015 3:43pm
108 Views
Post# 23953948

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:and meanwhile back in china hepa is still not trading...PoC.  At the risk of being banned somewhere I agree that non-compliance issues are to be expected but to happen to the degree that they happenned in ASSURE seems very sloppy to me.  Especially wrt the non-adherence to the blood lipid criterion.  People with heart disease and HDL levels below 40mg/dl are not exactly rare.

In answer to your successful biotech's with original founder's the two that come to my mind are Eugene Melnyk and David Allan of Biovail and YM Biosciences respectively.  But I think to your point,  they are the exceptions not the rule.  I wrote a post on the the other board a little while ago about my past dissappointment with the RVX miss on Roger Newton.  He in fact is another successful founder however he is also a rarity with both deep business and science credentials.
Bullboard Posts